Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Human Papillomavirus 16 Capsids Mediate Nuclear Entry during Infection.

Day PM, Weisberg AS, Thompson CD, Hughes MM, Pang YY, Lowy DR, Schiller JT.

J Virol. 2019 Jul 17;93(15). pii: e00454-19. doi: 10.1128/JVI.00454-19. Print 2019 Aug 1.

PMID:
31092566
2.

A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells.

Çuburu N, Kim R, Guittard GC, Thompson CD, Day PM, Hamm DE, Pang YS, Graham BS, Lowy DR, Schiller JT.

J Immunol. 2019 Feb 15;202(4):1250-1264. doi: 10.4049/jimmunol.1800219. Epub 2019 Jan 11.

PMID:
30635393
3.

Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial.

Magnan S, Tota JE, El-Zein M, Burchell AN, Schiller JT, Ferenczy A, Tellier PP, Coutlée F, Franco EL; CATCH Study Group.

Clin Microbiol Infect. 2019 Feb;25(2):210-216. doi: 10.1016/j.cmi.2018.04.012. Epub 2018 Apr 21.

PMID:
29684633
4.

Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies.

Kreimer AR, Herrero R, Sampson JN, Porras C, Lowy DR, Schiller JT, Schiffman M, Rodriguez AC, Chanock S, Jimenez S, Schussler J, Gail MH, Safaeian M, Kemp TJ, Cortes B, Pinto LA, Hildesheim A, Gonzalez P; Costa Rica HPV Vaccine Trial (CVT) Group.

Vaccine. 2018 Aug 6;36(32 Pt A):4774-4782. doi: 10.1016/j.vaccine.2017.12.078. Epub 2018 Feb 1.

5.

An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma.

Kines RC, Varsavsky I, Choudhary S, Bhattacharya D, Spring S, McLaughlin R, Kang SJ, Grossniklaus HE, Vavvas D, Monks S, MacDougall JR, de Los Pinos E, Schiller JT.

Mol Cancer Ther. 2018 Feb;17(2):565-574. doi: 10.1158/1535-7163.MCT-17-0953. Epub 2017 Dec 14.

6.

Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteins.

Çuburu N, Khan S, Thompson CD, Kim R, Vellinga J, Zahn R, Lowy DR, Scheper G, Schiller JT.

Int J Cancer. 2018 Apr 1;142(7):1467-1479. doi: 10.1002/ijc.31166. Epub 2017 Dec 1.

7.

Preventing Cancer and Other Diseases Caused by Human Papillomavirus Infection: 2017 Lasker-DeBakey Clinical Research Award.

Lowy DR, Schiller JT.

JAMA. 2017 Sep 12;318(10):901-902. doi: 10.1001/jama.2017.11706. No abstract available.

8.

Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions.

Cerqueira C, Thompson CD, Day PM, Pang YS, Lowy DR, Schiller JT.

Mol Ther Methods Clin Dev. 2017 Apr 19;5:165-179. doi: 10.1016/j.omtm.2017.04.005. eCollection 2017 Jun 16.

9.

Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases.

Berman TA, Schiller JT.

Cancer. 2017 Jun 15;123(12):2219-2229. doi: 10.1002/cncr.30588. Epub 2017 Mar 27. Review.

10.

Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism.

Day PM, Thompson CD, Lowy DR, Schiller JT.

J Virol. 2017 Apr 28;91(10). pii: e00168-17. doi: 10.1128/JVI.00168-17. Print 2017 May 15.

11.

Papillomavirus assembly: An overview and perspectives.

Cerqueira C, Schiller JT.

Virus Res. 2017 Mar 2;231:103-107. doi: 10.1016/j.virusres.2016.11.010. Epub 2016 Nov 10. Review.

12.

Leveraging premalignant biology for immune-based cancer prevention.

Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10750-8. doi: 10.1073/pnas.1608077113. Epub 2016 Sep 16.

13.

The Potential Benefits of HPV Vaccination in Previously Infected Women.

Schiller JT.

EBioMedicine. 2016 Aug;10:5-6. doi: 10.1016/j.ebiom.2016.08.005. Epub 2016 Aug 3. No abstract available.

14.

Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer.

Hojeij R, Domingos-Pereira S, Nkosi M, Gharbi D, Derré L, Schiller JT, Jichlinski P, Nardelli-Haefliger D.

Int J Mol Sci. 2016 Jul 14;17(7). pii: E1125. doi: 10.3390/ijms17071125.

15.

Involvement of Nucleophosmin (NPM1/B23) in Assembly of Infectious HPV16 Capsids.

Day PM, Thompson CD, Pang YY, Lowy DR, Schiller JT.

Papillomavirus Res. 2015 Dec;1:74-89. Epub 2015 Jun 25.

16.

Moving forward with human papillomavirus immunotherapies.

Çuburu N, Schiller JT.

Hum Vaccin Immunother. 2016 Nov;12(11):2875-2880. Epub 2016 Jul 7.

17.

Bacterial superglue enables easy development of efficient virus-like particle based vaccines.

Thrane S, Janitzek CM, Matondo S, Resende M, Gustavsson T, de Jongh WA, Clemmensen S, Roeffen W, van de Vegte-Bolmer M, van Gemert GJ, Sauerwein R, Schiller JT, Nielsen MA, Theander TG, Salanti A, Sander AF.

J Nanobiotechnology. 2016 Apr 27;14:30. doi: 10.1186/s12951-016-0181-1.

18.

Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.

Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, Porras C, Schiffman M, Sidawy M, Schiller JT, Lowy DR, Herrero R; Costa Rica HPV Vaccine Trial (CVT) Group.

Am J Obstet Gynecol. 2016 Aug;215(2):212.e1-212.e15. doi: 10.1016/j.ajog.2016.02.021. Epub 2016 Feb 16.

19.

A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging.

Cerqueira C, Pang YY, Day PM, Thompson CD, Buck CB, Lowy DR, Schiller JT.

J Virol. 2015 Nov 11;90(2):1096-107. doi: 10.1128/JVI.02497-15. Print 2016 Jan 15.

20.

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.

Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, Lowy DR, Porras C, Schiller JT, Quint W, Jimenez S, Safaeian M, Struijk L, Schussler J, Hildesheim A, Gonzalez P; Costa Rica HPV Vaccine Trial (CVT) Group.

J Natl Cancer Inst. 2015 Oct 14;108(1). pii: djv302. doi: 10.1093/jnci/djv302. Print 2016 Jan.

21.

A cholesterol-lowering VLP vaccine that targets PCSK9.

Crossey E, Amar MJA, Sampson M, Peabody J, Schiller JT, Chackerian B, Remaley AT.

Vaccine. 2015 Oct 26;33(43):5747-5755. doi: 10.1016/j.vaccine.2015.09.044. Epub 2015 Sep 26.

22.

Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide Vaccines.

Correia-Pinto JF, Csaba N, Schiller JT, Alonso MJ.

Vaccines (Basel). 2015 Sep 11;3(3):730-50. doi: 10.3390/vaccines3030730.

23.

Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial.

Panagiotou OA, Befano BL, Gonzalez P, Rodríguez AC, Herrero R, Schiller JT, Kreimer AR, Schiffman M, Hildesheim A, Wilcox AJ, Wacholder S; Costa Rica HPV Vaccine Trial (CVT) Group (see end of manuscript for full list of investigators).

BMJ. 2015 Sep 7;351:h4358. doi: 10.1136/bmj.h4358.

24.

Human papillomavirus capsids preferentially bind and infect tumor cells.

Kines RC, Cerio RJ, Roberts JN, Thompson CD, de Los Pinos E, Lowy DR, Schiller JT.

Int J Cancer. 2016 Feb 15;138(4):901-11. doi: 10.1002/ijc.29823. Epub 2015 Oct 27.

25.

Reply to Nalin.

Schiller JT, Lowy DR.

J Infect Dis. 2015 Dec 15;212(12):2021-2. doi: 10.1093/infdis/jiv394. Epub 2015 Aug 12. No abstract available.

26.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial Study Group Authors, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors, Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group.

Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.

27.

Next generation prophylactic human papillomavirus vaccines.

Schiller JT, Müller M.

Lancet Oncol. 2015 May;16(5):e217-25. doi: 10.1016/S1470-2045(14)71179-9. Review.

PMID:
25943066
28.

Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.

Kines RC, Zarnitsyn V, Johnson TR, Pang YY, Corbett KS, Nicewonger JD, Gangopadhyay A, Chen M, Liu J, Prausnitz MR, Schiller JT, Graham BS.

PLoS One. 2015 Mar 18;10(3):e0120797. doi: 10.1371/journal.pone.0120797. eCollection 2015.

29.

The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membrane.

Day PM, Thompson CD, Lowy DR, Schiller JT.

Virology. 2015 Jul;481:79-94. doi: 10.1016/j.virol.2015.02.021. Epub 2015 Mar 12.

30.

Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE.

Hum Vaccin Immunother. 2014;10(12):3446-54. doi: 10.4161/hv.34408.

31.

Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.

Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M, Rodriguez AC, Wacholder S, Gonzalez P, Schiller JT, Lowy DR, Esser M, Matys K, Poncelet S, Herrero R, Hildesheim A, Pinto LA, Safaeian M.

Hum Vaccin Immunother. 2014;10(10):2965-74. doi: 10.4161/21645515.2014.972811.

32.

Raising expectations for subunit vaccine.

Schiller JT, Lowy DR.

J Infect Dis. 2015 May 1;211(9):1373-5. doi: 10.1093/infdis/jiu648. Epub 2014 Nov 24. Review.

33.

Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.

Gordon SN, Doster MN, Kines RC, Keele BF, Brocca-Cofano E, Guan Y, Pegu P, Liyanage NP, Vaccari M, Cuburu N, Buck CB, Ferrari G, Montefiori D, Piatak M Jr, Lifson JD, Xenophontos AM, Venzon D, Robert-Guroff M, Graham BS, Lowy DR, Schiller JT, Franchini G.

J Immunol. 2014 Dec 15;193(12):6172-83. doi: 10.4049/jimmunol.1401504. Epub 2014 Nov 14.

34.
35.

Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.

Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, Kreimer AR, Poncelet S, Schussler J, Quint W, van Doorn LJ, Sherman ME, Sidawy M, Herrero R, Hildesheim A, Safaeian M; Costa Rica Vaccine Trial Group.

Am J Epidemiol. 2014 Sep 15;180(6):599-607. doi: 10.1093/aje/kwu168. Epub 2014 Aug 19.

36.

Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1.

Handisurya A, Day PM, Thompson CD, Bonelli M, Lowy DR, Schiller JT.

PLoS Pathog. 2014 Aug 14;10(8):e1004314. doi: 10.1371/journal.ppat.1004314. eCollection 2014 Aug.

37.

Maturation of the human papillomavirus 16 capsid.

Cardone G, Moyer AL, Cheng N, Thompson CD, Dvoretzky I, Lowy DR, Schiller JT, Steven AC, Buck CB, Trus BL.

MBio. 2014 Aug 5;5(4):e01104-14. doi: 10.1128/mBio.01104-14.

38.

Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.

Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, Chen S, Quint W, Lowy DR, Porras C, DelVecchio C, Jimenez S, Safaeian M, Schiller JT, Wacholder S, Herrero R, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2014 Dec 15;210(12):1890-9. doi: 10.1093/infdis/jiu357. Epub 2014 Jun 23.

39.

Large scale RNAi reveals the requirement of nuclear envelope breakdown for nuclear import of human papillomaviruses.

Aydin I, Weber S, Snijder B, Samperio Ventayol P, Kühbacher A, Becker M, Day PM, Schiller JT, Kann M, Pelkmans L, Helenius A, Schelhaas M.

PLoS Pathog. 2014 May 29;10(5):e1004162. doi: 10.1371/journal.ppat.1004162. eCollection 2014 May.

40.

Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

Kalnin K, Tibbitts T, Yan Y, Stegalkina S, Shen L, Costa V, Sabharwal R, Anderson SF, Day PM, Christensen N, Schiller JT, Jagu S, Roden RB, Almond J, Kleanthous H.

Vaccine. 2014 Jun 12;32(28):3540-7. doi: 10.1016/j.vaccine.2014.04.032. Epub 2014 Apr 26.

41.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of ICO Monograph Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 31;31 Suppl 7:H1-31. doi: 10.1016/j.vaccine.2013.10.003.

PMID:
24332295
42.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 30;31 Suppl 6:G1-31. doi: 10.1016/j.vaccine.2013.10.002. Review.

PMID:
24331817
43.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 29;31 Suppl 5:F1-31. doi: 10.1016/j.vaccine.2013.10.001. Review.

PMID:
24331745
44.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Nov 22;31 Suppl 8:I1-31. doi: 10.1016/j.vaccine.2013.07.026. Review.

45.

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA; CVT Group.

Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50. doi: 10.1158/1940-6207.CAPR-13-0203. Erratum in: Cancer Prev Res (Phila). 2016 Jan;9(1):116-7.

46.

Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization.

Handisurya A, Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT.

J Virol. 2013 Dec;87(24):13214-25. doi: 10.1128/JVI.02162-13. Epub 2013 Sep 25.

47.

Virus infection and human cancer: an overview.

Schiller JT, Lowy DR.

Recent Results Cancer Res. 2014;193:1-10. doi: 10.1007/978-3-642-38965-8_1.

PMID:
24008290
48.

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.

Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR; CVT Vaccine Group.

PLoS One. 2013 Jul 17;8(7):e68329. doi: 10.1371/journal.pone.0068329. Print 2013.

49.

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.

Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.

Hum Vaccin Immunother. 2013 Jul;9(7):1399-406. doi: 10.4161/hv.24340. Epub 2013 Apr 9.

50.

Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang HK, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB.

J Virol. 2013 Jun;87(11):6127-36. doi: 10.1128/JVI.03218-12. Epub 2013 Mar 27.

Supplemental Content

Loading ...
Support Center